Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made.
"synopsis" may belong to another edition of this title.
Seller: Brook Bookstore On Demand, Napoli, NA, Italy
Condition: new. Questo è un articolo print on demand. Seller Inventory # PBAHQG9DJI
Quantity: Over 20 available
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition. Seller Inventory # 14384726
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 14384726-n
Seller: California Books, Miami, FL, U.S.A.
Condition: New. Seller Inventory # I-9781617377563
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made. 292 pp. Englisch. Seller Inventory # 9781617377563
Seller: moluna, Greven, Germany
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licen. Seller Inventory # 458521613
Quantity: Over 20 available
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Condition: New. Editor(s): Saltz, Leonard B. Series: Current Clinical Oncology. Num Pages: 302 pages, 42 black & white illustrations, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 17. Weight in Grams: 450. . 2010. 1st ed. Softcover of orig. ed. 2007. Paperback. . . . . Seller Inventory # V9781617377563
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Management options for patients with colorectal cancer have undergone d- matic changes over the past decade. Whereas at the start of 1996 only one drug, 5-Fluorouracil, was available for the treatment of this disease, a mere 10 yr later, six drugs are licensed for use in colorectal cancer, and others are in the late phases of clinical development. Likewise, surgical and ablative options, as well as an array of supportive medications, have shown substantial progress and undergone a dramatic proliferation over the past decade. With the increased number of therapeutic options from which to choose, the clinician is better able to offer effective therapy to the patient with colorectal cancer. The clinician is challenged, however, to keep up with the rapidly changing landscape and the rapidly emerging data that shape the options for treatment today and tom- row. In this text, leaders in the management of colorectal cancer review the current literature that has led us to where we are today. Critical evaluations of the data are offered, and evidence-based recommendations are made. Seller Inventory # 9781617377563
Seller: Books Puddle, Woodside, NY, U.S.A.
Condition: New. pp. 304. Seller Inventory # 263101822
Seller: preigu, Osnabrück, Germany
Taschenbuch. Condition: Neu. Colorectal Cancer | Evidence-Based Chemotherapy Strategies | Leonard B Saltz | Taschenbuch | x | Englisch | 2010 | Humana Press | EAN 9781617377563 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. Seller Inventory # 107146351